The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade

Drug Resistance Updates

Volumn 18, Issue , 2015, Pages 1-17

  Kathawala, Rishil J ^a   Gupta, Pranav ^a   Ashby, Charles R ^a   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

ABC transporters; Marine sponges; Modulators; Multidrug resistance; Natural products; Phosphodiesterase inhibitors; Tyrosine kinase inhibitors

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; AST 1306; BREAST CANCER RESISTANCE PROTEIN; BRYOSTATIN 1; CANERTINIB; CRIZOTINIB; EPIGALLOCATECHIN GALLATE; ERLOTINIB; GEFITINIB; ICOTINIB; IMATINIB; LAPATINIB; LINSITINIB; MASITINIB; MOTESANIB; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 7; MULTIDRUG RESISTANCE PROTEIN 1; NILOTINIB; PLANT MEDICINAL PRODUCT; PONATINIB; SORAFENIB; SUNITINIB; TELATINIB; TRABECTEDIN; TRITERPENOID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; VEMURAFENIB;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; CYTOTOXICITY; ENZYME ACTIVITY; HUMAN; HYDROLYSIS; MULTIDRUG RESISTANCE; NEOPLASM; NON SMALL CELL LUNG CANCER; NONHUMAN; NUTRITION; PATHOGENESIS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; SPOROGENESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; DRUG RESISTANCE; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS;

EID: 84922223032     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2014.11.002     Document Type: Review

References (239)

1. B.L. Abbott, A.M. Colapietro, Y. Barnes, F. Marini, M. Andreeff, and B.P. Sorrentino Low levels of ABCG2 expression in adult AML blast samples Blood 100 2002 4594 4601
2. I. Abraham, K. El Sayed, Z.S. Chen, and H. Guo Current status on marine products with reversal effect on cancer multidrug resistance Mar. Drugs 10 2012 2312 2321
3. R. Advani, G.A. Fisher, B.L. Lum, J. Hausdorff, J. Halsey, M. Litchman, and B.I. Sikic A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance Clin. Cancer Res. 7 2001 1221 1229
4. M. Alvarez, K. Paull, A. Monks, C. Hose, J.S. Lee, J. Weinstein, M. Grever, S. Bates, and T. Fojo Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen J. Clin. Invest. 95 1995 2205 2214
5. S.V. Ambudkar, I.W. Kim, D. Xia, and Z.E. Sauna The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding FEBS Lett. 580 2006 1049 1055
6. N. Anreddy, P. Gupta, R.J. Kathawala, A. Patel, J.N. Wurpel, and Z.S. Chen Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance Molecules 19 2014 13848 13877
7. S. Aoki, Z.S. Chen, K. Higasiyama, A. Setiawan, S. Akiyama, and M. Kobayashi Reversing effect of agosterol A, a spongean sterol acetate, on multidrug resistance in human carcinoma cells Jpn. J. Cancer Res. 92 2001 886 895
8. C.L. Arteaga The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia J. Clin. Oncol. 19 2001 32S 40S
9. Y.G. Assaraf Molecular basis of antifolate resistance Cancer Metastasis Rev. 26 2007 153 181
10. Y.G. Assaraf, and M.J. Borgnia Differential reversal of lipophilic antifolate resistance in mammalian cells with modulators of the multidrug resistance phenotype Anticancer Drugs 4 1993 395 406
11. Y.G. Assaraf, S. Drori, U. Bachrach, and V. Shaugan-Labay Determination of multidrug resistance levels in cultured mammalian cells using ornithine decarboxylase activity Anal. Biochem. 216 1994 97 109
12. Y.G. Assaraf, A. Molina, and R.T. Schimke Sequential amplification of dihydrofolate reductase and multidrug resistance genes in Chinese hamster ovary cells selected for stepwise resistance to the lipid-soluble antifolate trimetrexate J. Biol. Chem. 264 1989 18326 18334
13. Y.G. Assaraf, L. Rothem, J.H. Hooijberg, M. Stark, I. Ifergan, I. Kathmann, B.A. Dijkmans, G.J. Peters, and G. Jansen Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells J. Biol. Chem. 278 2003 6680 6686
14. M.R. Baer, S.L. George, R.K. Dodge, K.L. O'Loughlin, H. Minderman, M.A. Caligiuri, J. Anastasi, B.L. Powell, J.E. Kolitz, C.A. Schiffer, C.D. Bloomfield, and R.A. Larson Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720 Blood 100 2002 1224 1232
15. E. Bakos, R. Evers, G. Szakacs, G.E. Tusnady, E. Welker, K. Szabo, M. de Haas, L. van Deemter, P. Borst, A. Varadi, and B. Sarkadi Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain J. Biol. Chem. 273 1998 32167 32175
16. N.L. Bartlett, B.L. Lum, G.A. Fisher, N.A. Brophy, M.N. Ehsan, J. Halsey, and B.I. Sikic Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance J. Clin. Oncol. 12 1994 835 842
17. S.E. Bates, W.Y. Medina-Perez, G. Kohlhagen, S. Antony, T. Nadjem, R.W. Robey, and Y. Pommier ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins J. Pharmacol. Exp. Ther. 310 2004 836 842
18. S.F. Bates, C. Chen, R. Robey, M. Kang, W.D. Figg, and T. Fojo Reversal of multidrug resistance: lessons from clinical oncology Novartis Found. Symp. 243 2002 83 96 discussion 96-102, 180-105
19. Y. Bessho, T. Oguri, H. Ozasa, T. Uemura, H. Sakamoto, M. Miyazaki, K. Maeno, S. Sato, and R. Ueda ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer Oncol. Rep. 21 2009 263 268
20. E.L. Borths, K.P. Locher, A.T. Lee, and D.C. Rees The structure of Escherichia coli BtuF and binding to its cognate ATP binding cassette transporter Proc. Natl. Acad. Sci. U. S. A. 99 2002 16642 16647
21. P.S. Changelian, D. Moshinsky, C.F. Kuhn, M.E. Flanagan, M.J. Munchhof, T.M. Harris, D.A. Whipple, J.L. Doty, J. Sun, C.R. Kent, K.S. Magnuson, D.G. Perregaux, P.S. Sawyer, and E.M. Kudlacz The specificity of JAK3 kinase inhibitors Blood 111 2008 2155 2157
22. W. Chearwae, S. Shukla, P. Limtrakul, and S.V. Ambudkar Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin Mol. Cancer Ther. 5 2006 1995 2006
23. J.J. Chen, Y.L. Sun, A.K. Tiwari, Z.J. Xiao, K. Sodani, D.H. Yang, S.G. Vispute, W.Q. Jiang, S.D. Chen, and Z.S. Chen PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter Cancer Sci. 103 2012 1531 1537
24. K.G. Chen, and B.I. Sikic Molecular pathways: regulation and therapeutic implications of multidrug resistance Clin. Cancer Res. 18 2012 1863 1869
25. Z.S. Chen, S. Aoki, M. Komatsu, K. Ueda, T. Sumizawa, T. Furukawa, H. Okumura, X.Q. Ren, M.G. Belinsky, K. Lee, G.D. Kruh, M. Kobayashi, and S. Akiyama Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function Int. J. Cancer 93 2001 107 113
26. Z.S. Chen, E. Hopper-Borge, M.G. Belinsky, I. Shchaveleva, E. Kotova, and G.D. Kruh Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10) Mol. Pharmacol. 63 2003 351 358
27. Z.S. Chen, R.W. Robey, M.G. Belinsky, I. Shchaveleva, X.Q. Ren, Y. Sugimoto, D.D. Ross, S.E. Bates, and G.D. Kruh Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-d-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport Cancer Res. 63 2003 4048 4054
28. Z.S. Chen, T. Sumizawa, T. Furukawa, K. Ono, A. Tani, M. Komatsu, and S. Akiyama An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells Cancer Lett. 138 1999 13 22
29. K.H. Choi, C.J. Chen, M. Kriegler, and I.B. Roninson An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene Cell 53 1988 519 529
30. S.P. Cole, G. Bhardwaj, J.H. Gerlach, J.E. Mackie, C.E. Grant, K.C. Almquist, A.J. Stewart, E.U. Kurz, A.M. Duncan, and R.G. Deeley Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science 258 1992 1650 1654
31. S.P. Cole, K.E. Sparks, K. Fraser, D.W. Loe, C.E. Grant, G.M. Wilson, and R.G. Deeley Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells Cancer Res. 54 1994 5902 5910
32. H.M. Coley Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors Methods Mol. Biol. 596 2010 341 358
33. H.C. Cooray, C.G. Blackmore, L. Maskell, and M.A. Barrand Localisation of breast cancer resistance protein in microvessel endothelium of human brain Neuroreport 13 2002 2059 2063
34. K. Czyzewski, and J. Styczynski Imatinib is a substrate for various multidrug resistance proteins Neoplasma 56 2009 202 207
35. M. Dabrowska, and F.M. Sirotnak Regulation of transcription of the human MRP7 gene. Characteristics of the basal promoter and identification of tumor-derived transcripts encoding additional 5′ end heterogeneity Gene 341 2004 129 139
36. C.L. Dai, Y.J. Liang, Y.S. Wang, A.K. Tiwari, Y.Y. Yan, F. Wang, Z.S. Chen, X.Z. Tong, and L.W. Fu Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2 Cancer Lett. 279 2009 74 83
37. C.L. Dai, A.K. Tiwari, C.P. Wu, X.D. Su, S.R. Wang, D.G. Liu, C.R. Ashby Jr., Y. Huang, R.W. Robey, Y.J. Liang, L.M. Chen, C.J. Shi, S.V. Ambudkar, Z.S. Chen, and L.W. Fu Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 Cancer Res. 68 2008 7905 7914
38. W.S. Dalton, J.J. Crowley, S.S. Salmon, T.M. Grogan, L.R. Laufman, G.R. Weiss, and J.D. Bonnet A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study Cancer 75 1995 815 820
39. A.H. Dantzig, R.L. Shepard, K.L. Law, L. Tabas, S. Pratt, J.S. Gillespie, S.N. Binkley, M.T. Kuhfeld, J.J. Starling, and S.A. Wrighton Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities J. Pharmacol. Exp. Ther. 290 1999 854 862
40. R. De Souza, P. Zahedi, R.M. Badame, C. Allen, and M. Piquette-Miller Chemotherapy dosing schedule influences drug resistance development in ovarian cancer Mol. Cancer Ther. 10 2011 1289 1299
41. M. Dean ABC transporters, drug resistance, and cancer stem cells J. Mammary Gland Biol. Neoplasia 14 2009 3 9
42. M. Dean, and R. Allikmets Evolution of ATP-binding cassette transporter genes Curr. Opin. Genet. Dev. 5 1995 779 785
43. M. Dean, and T. Annilo Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates Annu. Rev. Genomics Hum. Genet. 6 2005 123 142
44. M. Dean, A. Rzhetsky, and R. Allikmets The human ATP-binding cassette (ABC) transporter superfamily Genome Res. 11 2001 1156 1166
45. R.G. Deeley, C. Westlake, and S.P. Cole Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins Physiol. Rev. 86 2006 849 899
46. W. Deng, C.L. Dai, J.J. Chen, R.J. Kathawala, Y.L. Sun, H.F. Chen, L.W. Fu, and Z.S. Chen Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10) Oncol. Rep. 29 2013 2479 2485
47. S.E. Devine, V. Ling, and P.W. Melera Amino acid substitutions in the sixth transmembrane domain of P-glycoprotein alter multidrug resistance Proc. Natl. Acad. Sci. U. S. A. 89 1992 4564 4568
48. P.R. Ding, A.K. Tiwari, S. Ohnuma, J.W. Lee, X. An, C.L. Dai, Q.S. Lu, S. Singh, D.H. Yang, T.T. Talele, S.V. Ambudkar, and Z.S. Chen The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter PLoS ONE 6 2011 e19329
49. L.A. Doyle, W. Yang, L.V. Abruzzo, T. Krogmann, Y. Gao, A.K. Rishi, and D.D. Ross A multidrug resistance transporter from human MCF-7 breast cancer cells Proc. Natl. Acad. Sci. U. S. A. 95 1998 15665 15670
50. P. Dubreuil, S. Letard, M. Ciufolini, L. Gros, M. Humbert, N. Casteran, L. Borge, B. Hajem, A. Lermet, W. Sippl, E. Voisset, M. Arock, C. Auclair, P.S. Leventhal, C.D. Mansfield, A. Moussy, and O. Hermine Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT PLoS ONE 4 2009 e7258
51. K.F. Ejendal, N.K. Diop, L.C. Schweiger, and C.A. Hrycyna The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding Protein Sci. 15 2006 1597 1607
52. K.F. Ejendal, and C.A. Hrycyna Multidrug resistance and cancer: the role of the human ABC transporter ABCG2 Curr. Protein Pept. Sci. 3 2002 503 511
53. P.M. Ellis, and K. Al-Saleh Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions Crit. Rev. Oncol. Hematol. 84 2012 47 58
54. C. Erlichman, S.A. Boerner, C.G. Hallgren, R. Spieker, X.Y. Wang, C.D. James, G.L. Scheffer, M. Maliepaard, D.D. Ross, K.C. Bible, and S.H. Kaufmann The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux Cancer Res. 61 2001 739 748
55. F.A. Eskens, N. Steeghs, J. Verweij, J.L. Bloem, O. Christensen, L. van Doorn, J. Ouwerkerk, M.J. de Jonge, J.W. Nortier, J. Kraetzschmar, P. Rajagopalan, and H. Gelderblom Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors J. Clin. Oncol. 27 2009 4169 4176
56. G.D. Eytan, R. Regev, and Y.G. Assaraf Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis J. Biol. Chem. 271 1996 3172 3178
57. S. Findling-Kagan, H. Sivan, O. Ostrovsky, A. Nagler, and H. Galski Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1 Leuk. Res. 29 2005 407 414
58. P.M. Fracasso, L.J. Goldstein, D.P. de Alwis, J.S. Rader, M.A. Arquette, S.A. Goodner, L.P. Wright, C.L. Fears, R.J. Gazak, V.A. Andre, M.F. Burgess, C.A. Slapak, and J.H. Schellens Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies Clin. Cancer Res. 10 2004 7220 7228
59. R.I. Freshney ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein Br. J. Cancer 97 2007 1714 author reply 1715
60. T.H. Fu, W.T. McElroy, M. Shamszad, and S.F. Martin Formal syntheses of naturally occurring welwitindolinones Org. Lett. 14 2012 3834 3837
61. H.K. Gan, B. Seruga, and J.J. Knox Sunitinib in solid tumors Expert Opin. Investig. Drugs 18 2009 821 834
62. L. Gao, L. Chen, X.H. Fei, H.Y. Qiu, H. Zhou, and J.M. Wang STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model Chin. Med. J. (Engl.) 119 2006 911 918
63. Z. Gao, W. Chen, X. Zhang, P. Cai, X. Fang, Q. Xu, Y. Sun, and Y. Gu Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling Biomed. Pharmacother. 67 2013 351 356
64. M.L. Gild, M. Bullock, B.G. Robinson, and R. Clifton-Bligh Multikinase inhibitors: a new option for the treatment of thyroid cancer Nat. Rev. Endocrinol. 7 2011 617 624
65. J.P. Gillet, and M.M. Gottesman Mechanisms of multidrug resistance in cancer Methods Mol. Biol. 596 2010 47 76
66. H. Glavinas, P. Krajcsi, J. Cserepes, and B. Sarkadi The role of ABC transporters in drug resistance, metabolism and toxicity Curr. Drug Deliv. 1 2004 27 42
67. B. Goldman Multidrug resistance: can new drugs help chemotherapy score against cancer? J. Natl. Cancer Inst. 95 2003 255 257
68. J.M. Goldman, and J.V. Melo Chronic myeloid leukemia - advances in biology and new approaches to treatment N. Engl. J. Med. 349 2003 1451 1464
69. L.J. Goldstein, H. Galski, A. Fojo, M. Willingham, S.L. Lai, A. Gazdar, R. Pirker, A. Green, W. Crist, and G.M. Brodeur Expression of a multidrug resistance gene in human cancers J. Natl. Cancer Inst. 81 1989 116 124
70. V. Goler-Baron, and Y.G. Assaraf Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance PLoS ONE 6 2011 e16007
71. M.M. Gottesman, and S.V. Ambudkar Overview: ABC transporters and human disease J. Bioenerg. Biomembr. 33 2001 453 458
72. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 2002 48 58
73. H. Green, P. Soderkvist, P. Rosenberg, G. Horvath, and C. Peterson ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel J. Pharm. Sci. 97 2008 2045 2048
74. H. Green, P. Soderkvist, P. Rosenberg, G. Horvath, and C. Peterson mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy Clin. Cancer Res. 12 2006 854 859
75. C. Grimm, S. Polterauer, R. Zeillinger, D. Tong, G. Heinze, A. Wolf, C. Natter, A. Reinthaller, and L.A. Hefler Two multidrug-resistance (ABCB1) gene polymorphisms as prognostic parameters in women with ovarian cancer Anticancer Res. 30 2010 3487 3491
76. P. Gros, R. Dhir, J. Croop, and F. Talbot A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps Proc. Natl. Acad. Sci. U. S. A. 88 1991 7289 7293
77. A. Henningsson, S. Marsh, W.J. Loos, M.O. Karlsson, A. Garsa, K. Mross, S. Mielke, L. Vigano, A. Locatelli, J. Verweij, A. Sparreboom, and H.L. McLeod Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel Clin. Cancer Res. 11 2005 8097 8104
78. C.F. Higgins ABC transporters: from microorganisms to man Annu. Rev. Cell Biol. 8 1992 67 113
79. C.F. Higgins, I.D. Hiles, K. Whalley, and D.J. Jamieson Nucleotide binding by membrane components of bacterial periplasmic binding protein-dependent transport systems EMBO J. 4 1985 1033 1039
80. S. Hirota, K. Isozaki, Y. Moriyama, K. Hashimoto, T. Nishida, S. Ishiguro, K. Kawano, M. Hanada, A. Kurata, M. Takeda, G. Muhammad Tunio, Y. Matsuzawa, Y. Kanakura, Y. Shinomura, and Y. Kitamura Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 1998 577 580
81. C. Hirschmann-Jax, A.E. Foster, G.G. Wulf, J.G. Nuchtern, T.W. Jax, U. Gobel, M.A. Goodell, and M.K. Brenner A distinct "side population" of cells with high drug efflux capacity in human tumor cells Proc. Natl. Acad. Sci. U. S. A. 101 2004 14228 14233
82. I.B. Holland ABC transporters, mechanisms and biology: an overview Essays Biochem. 50 2011 1 17
83. Y. Honjo, C.A. Hrycyna, Q.W. Yan, W.Y. Medina-Perez, R.W. Robey, A. van de Laar, T. Litman, M. Dean, and S.E. Bates Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells Cancer Res. 61 2001 6635 6639
84. J.H. Hooijberg, H.J. Broxterman, M. Kool, Y.G. Assaraf, G.J. Peters, P. Noordhuis, R.J. Scheper, P. Borst, H.M. Pinedo, and G. Jansen Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2 Cancer Res. 59 1999 2532 2535
85. E. Hopper-Borge, Z.S. Chen, I. Shchaveleva, M.G. Belinsky, and G.D. Kruh Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel Cancer Res. 64 2004 4927 4930
86. E. Hopper-Borge, X. Xu, T. Shen, Z. Shi, Z.S. Chen, and G.D. Kruh Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B Cancer Res. 69 2009 178 184
87. E.A. Hopper-Borge, T. Churchill, C. Paulose, E. Nicolas, J.D. Jacobs, O. Ngo, Y. Kuang, A. Grinberg, H. Westphal, Z.S. Chen, A.J. Klein-Szanto, M.G. Belinsky, and G.D. Kruh Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice Cancer Res. 71 2011 3649 3657
88. E. Hopper, M.G. Belinsky, H. Zeng, A. Tosolini, J.R. Testa, and G.D. Kruh Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily Cancer Lett. 162 2001 181 191
89. S. Hu, Z. Chen, R. Franke, S. Orwick, M. Zhao, M.A. Rudek, A. Sparreboom, and S.D. Baker Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters Clin. Cancer Res. 15 2009 6062 6069
90. S. Hu, H. Niu, H. Inaba, S. Orwick, C. Rose, J.C. Panetta, S. Yang, S. Pounds, Y. Fan, C. Calabrese, J.E. Rehg, D. Campana, J.E. Rubnitz, and S.D. Baker Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia J. Natl. Cancer Inst. 103 2011 893 905
91. W.S. Huang, C.A. Metcalf, R. Sundaramoorthi, Y. Wang, D. Zou, R.M. Thomas, X. Zhu, L. Cai, D. Wen, S. Liu, J. Romero, J. Qi, I. Chen, G. Banda, S.P. Lentini, S. Das, Q. Xu, J. Keats, F. Wang, S. Wardwell, Y. Ning, J.T. Snodgrass, M.I. Broudy, K. Russian, T. Zhou, L. Commodore, N.I. Narasimhan, Q.K. Mohemmad, J. Iuliucci, V.M. Rivera, D.C. Dalgarno, T.K. Sawyer, T. Clackson, and W.C. Shakespeare Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-y l)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant J. Med. Chem. 53 2010 4701 4719
92. M.T. Huisman, A.A. Chhatta, O. van Tellingen, J.H. Beijnen, and A.H. Schinkel MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid Int. J. Cancer 116 2005 824 829
93. F. Hyafil, C. Vergely, P. Du Vignaud, and T. Grand-Perret In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative Cancer Res. 53 1993 4595 4602
94. I. Ifergan, A. Shafran, G. Jansen, J.H. Hooijberg, G.L. Scheffer, and Y.G. Assaraf Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis J. Biol. Chem. 279 2004 25527 25534
95. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA. Cancer J. Clin. 59 2009 225 249
96. N.E. Jordanides, H.G. Jorgensen, T.L. Holyoake, and J.C. Mountford Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate Blood 108 2006 1370 1373
97. R.L. Juliano, and V. Ling A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim. Biophys. Acta 455 1976 152 162
98. H. Kantarjian, F. Giles, L. Wunderle, K. Bhalla, S. O'Brien, B. Wassmann, C. Tanaka, P. Manley, P. Rae, W. Mietlowski, K. Bochinski, A. Hochhaus, J.D. Griffin, D. Hoelzer, M. Albitar, M. Dugan, J. Cortes, L. Alland, and O.G. Ottmann Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL N. Engl. J. Med. 354 2006 2542 2551
99. A. Kanzaki, Y. Takebayashi, X.Q. Ren, H. Miyashita, S. Mori, S. Akiyama, and Y. Pommier Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743 Mol. Cancer Ther. 1 2002 1327 1334
100. S. Karras, P. Anagnostis, and G.E. Krassas Vandetanib for the treatment of thyroid cancer: an update Expert Opin. Drug Metab. Toxicol. 10 2014 469 481
101. R.J. Kathawala, J.J. Chen, Y.K. Zhang, Y.J. Wang, A. Patel, D.S. Wang, T.T. Talele, C.R. Ashby Jr., and Z.S. Chen Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance Int. J. Oncol. 44 2014 1634 1642
102. R.J. Kathawala, K. Sodani, K. Chen, A. Patel, A.H. Abuznait, N. Anreddy, Y.L. Sun, A. Kaddoumi, C.R. Ashby Jr., and Z.S. Chen Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study Mol. Cancer Ther. 13 2014 714 723
103. R.J. Kathawala, Y.J. Wang, C.R. Ashby Jr., and Z.S. Chen Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs Chin. J. Cancer 33 2014 223 230
104. R.J. Kelly, R.W. Robey, C.C. Chen, D. Draper, V. Luchenko, D. Barnett, R.K. Oldham, Z. Caluag, A.R. Frye, S.M. Steinberg, T. Fojo, and S.E. Bates A pharmacodynamic study of the P-glycoprotein antagonist CBT-1(R) in combination with paclitaxel in solid tumors Oncologist 17 2012 512
105. J. Kim, X. Zhang, K.M. Rieger-Christ, I.C. Summerhayes, D.E. Wazer, K.E. Paulson, and A.S. Yee Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. Requirement of the transcriptional repressor HBP1 J. Biol. Chem. 281 2006 10865 10875
106. J.E. Kim, R.R. Singh, J.H. Cho-Vega, E. Drakos, Y. Davuluri, F.A. Khokhar, L. Fayad, L.J. Medeiros, and F. Vega Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma Mod. Pathol. 22 2009 1312 1320
107. Y.H. Kim, G. Ishii, K. Goto, S. Ota, K. Kubota, Y. Murata, M. Mishima, N. Saijo, Y. Nishiwaki, and A. Ochiai Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer Lung Cancer 65 2009 105 111
108. S. Kitagawa, T. Nabekura, and S. Kamiyama Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells J. Pharm. Pharmacol. 56 2004 1001 1005
109. S. Kitagawa, T. Takahashi, T. Nabekura, E. Tachikawa, and H. Hasegawa Inhibitory effects of ginsenosides and their hydrolyzed metabolites on daunorubicin transport in KB-C2 cells Biol. Pharm. Bull. 30 2007 1979 1981
110. T. Kitazaki, M. Oka, Y. Nakamura, J. Tsurutani, S. Doi, M. Yasunaga, M. Takemura, H. Yabuuchi, H. Soda, and S. Kohno Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells Lung Cancer 49 2005 337 343
111. S. Kohler, and W.D. Stein Optimizing chemotherapy by measuring reversal of P-glycoprotein activity in plasma membrane vesicles Biotechnol. Bioeng. 81 2003 507 517
112. G.D. Kruh, and M.G. Belinsky The MRP family of drug efflux pumps Oncogene 22 2003 7537 7552
113. G.D. Kruh, Y. Guo, E. Hopper-Borge, M.G. Belinsky, and Z.S. Chen ABCC10, ABCC11, and ABCC12 Pflugers Arch. 453 2007 675 684
114. Y.H. Kuang, T. Shen, X. Chen, K. Sodani, E. Hopper-Borge, A.K. Tiwari, J.W. Lee, L.W. Fu, and Z.S. Chen Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance Biochem. Pharmacol. 79 2010 154 161
115. P.L. Kunz, A.R. He, A.D. Colevas, M.J. Pishvaian, J.J. Hwang, P.L. Clemens, M. Messina, R. Kaleta, F. Abrahao, B.I. Sikic, and J.L. Marshall Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors Invest. New Drugs 30 2012 2364 2370
116. A. Le Cesne, J.Y. Blay, B.N. Bui, O. Bouche, A. Adenis, J. Domont, A. Cioffi, I. Ray-Coquard, N. Lassau, S. Bonvalot, A. Moussy, J.P. Kinet, and O. Hermine Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST) Eur. J. Cancer 46 2010 1344 1351
117. G.D. Leonard, T. Fojo, and S.E. Bates The role of ABC transporters in clinical practice Oncologist 8 2003 411 424
118. G. Leschziner, D. Zabaneh, M. Pirmohamed, A. Owen, J. Rogers, A.J. Coffey, D.J. Balding, D.B. Bentley, and M.R. Johnson Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance Pharmacogenet. Genomics 16 2006 439 450
119. P. Limtrakul, W. Chearwae, S. Shukla, C. Phisalphong, and S.V. Ambudkar Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin Mol. Cell. Biochem. 296 2007 85 95
120. Z.P. Lin, D.R. Johnson, R.A. Finch, M.G. Belinsky, G.D. Kruh, and A.C. Sartorelli Comparative study of the importance of multidrug resistance-associated protein 1 and P-glycoprotein to drug sensitivity in immortalized mouse embryonic fibroblasts Mol. Cancer Ther. 1 2002 1105 1114
121. A.F. List, K.J. Kopecky, C.L. Willman, D.R. Head, D.L. Persons, M.L. Slovak, R. Dorr, C. Karanes, H.E. Hynes, J.H. Doroshow, M. Shurafa, and F.R. Appelbaum Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study Blood 98 2001 3212 3220
122. T. Litman, M. Brangi, E. Hudson, P. Fetsch, A. Abati, D.D. Ross, K. Miyake, J.H. Resau, and S.E. Bates The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2) J. Cell Sci. 113 Pt 11 2000 2011 2021
123. J. Liu, H. Chen, D.S. Miller, J.E. Saavedra, L.K. Keefer, D.R. Johnson, C.D. Klaassen, and M.P. Waalkes Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic Mol. Pharmacol. 60 2001 302 309
124. J.A. Liu Yin, K. Wheatley, J.K. Rees, A.K. Burnett, and U.M.A.L.W. Party Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial Br. J. Haematol. 113 2001 713 726
125. K.P. Locher Structure and mechanism of ABC transporters Curr. Opin. Struct. Biol. 14 2004 426 431
126. K.P. Locher, and E. Borths ABC transporter architecture and mechanism: implications from the crystal structures of BtuCD and BtuF FEBS Lett. 564 2004 264 268
127. J.J. Luke, and F.S. Hodi Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma Clin. Cancer Res. 18 2012 9 14
128. B.L. Lum, and M.P. Gosland MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors Hematol. Oncol. Clin. North Am. 9 1995 319 336
129. B.L. Lum, S. Kaubisch, A.M. Yahanda, K.M. Adler, L. Jew, M.N. Ehsan, N.A. Brophy, J. Halsey, M.P. Gosland, and B.I. Sikic Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance J. Clin. Oncol. 10 1992 1635 1642
130. F.X. Mahon, S. Hayette, V. Lagarde, F. Belloc, B. Turcq, F. Nicolini, C. Belanger, P.W. Manley, C. Leroy, G. Etienne, S. Roche, and J.M. Pasquet Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression Cancer Res. 68 2008 9809 9816
131. M. Maliepaard, G.L. Scheffer, I.F. Faneyte, M.A. van Gastelen, A.C. Pijnenborg, A.H. Schinkel, M.J. van De Vijver, R.J. Scheper, and J.H. Schellens Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues Cancer Res. 61 2001 3458 3464
132. E.V. Malofeeva, N. Domanitskaya, M. Gudima, and E.A. Hopper-Borge Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7) Cancer Res. 72 2012 6457 6467
133. Q. Mao, and J.D. Unadkat Role of the breast cancer resistance protein (ABCG2) in drug transport AAPS J. 7 2005 E118 E133
134. S. Marchetti, N.A. de Vries, T. Buckle, M.J. Bolijn, M.A. van Eijndhoven, J.H. Beijnen, R. Mazzanti, O. van Tellingen, and J.H. Schellens Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice Mol. Cancer Ther. 7 2008 2280 2287
135. S. Marsh, J. Paul, C.R. King, G. Gifford, H.L. McLeod, and R. Brown Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer J. Clin. Oncol. 25 2007 4528 4535
136. C. Martin, G. Berridge, P. Mistry, C. Higgins, P. Charlton, and R. Callaghan The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein Br. J. Pharmacol. 128 1999 403 411
137. H. Matsubara, M. Watanabe, T. Imai, Y. Yui, Y. Mizushima, Y. Hiraumi, Y. Kamitsuji, K. Watanabe, K. Nishijo, J. Toguchida, T. Nakahata, and S. Adachi Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S, 4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone] J. Pharmacol. Exp. Ther. 328 2009 839 848
138. H. Matsuo, T. Takada, K. Ichida, T. Nakamura, A. Nakayama, Y. Takada, C. Okada, Y. Sakurai, T. Hosoya, Y. Kanai, H. Suzuki, and N. Shinomiya Identification of ABCG2 dysfunction as a major factor contributing to gout Nucleosides Nucleotides Nucleic Acids 30 2011 1098 1104
139. L.A. Mickley, B.A. Spengler, T.A. Knutsen, J.L. Biedler, and T. Fojo Gene rearrangement: a novel mechanism for MDR-1 gene activation J. Clin. Invest. 99 1997 1947 1957
140. M. Minocha, V. Khurana, B. Qin, D. Pal, and A.K. Mitra Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib Int. J. Pharm. 436 2012 127 134
141. P. Mistry, A.J. Stewart, W. Dangerfield, S. Okiji, C. Liddle, D. Bootle, J.A. Plumb, D. Templeton, and P. Charlton In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576 Cancer Res. 61 2001 749 758
142. C.S. Morrow, C. Peklak-Scott, B. Bishwokarma, T.E. Kute, P.K. Smitherman, and A.J. Townsend Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux Mol. Pharmacol. 69 2006 1499 1505
143. F. Morschhauser, P.L. Zinzani, M. Burgess, L. Sloots, F. Bouafia, and C. Dumontet Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma Leuk. Lymphoma 48 2007 708 715
144. J.D. Moyer, E.G. Barbacci, K.K. Iwata, L. Arnold, B. Boman, A. Cunningham, C. DiOrio, J. Doty, M.J. Morin, M.P. Moyer, M. Neveu, V.A. Pollack, L.R. Pustilnik, M.M. Reynolds, D. Sloan, A. Theleman, and P. Miller Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res. 57 1997 4838 4848
145. T. Nabekura Overcoming multidrug resistance in human cancer cells by natural compounds Toxins (Basel) 2 2010 1207 1224
146. T. Nabekura, S. Kamiyama, and S. Kitagawa Effects of dietary chemopreventive phytochemicals on P-glycoprotein function Biochem. Biophys. Res. Commun. 327 2005 866 870
147. T. Nabekura, T. Yamaki, T. Hiroi, K. Ueno, and S. Kitagawa Inhibition of anticancer drug efflux transporter P-glycoprotein by rosemary phytochemicals Pharmacol. Res. 61 2010 259 263
148. T. Nabekura, T. Yamaki, and S. Kitagawa Effects of chemopreventive citrus phytochemicals on human P-glycoprotein and multidrug resistance protein 1 Eur. J. Pharmacol. 600 2008 45 49
149. T. Nabekura, T. Yamaki, K. Ueno, and S. Kitagawa Effects of plant sterols on human multidrug transporters ABCB1 and ABCC1 Biochem. Biophys. Res. Commun. 369 2008 363 368
150. T. Nabekura, T. Yamaki, K. Ueno, and S. Kitagawa Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals Cancer Chemother. Pharmacol. 62 2008 867 873
151. M. Nakajima, Y. Fujiki, S. Kyo, T. Kanaya, M. Nakamura, Y. Maida, M. Tanaka, M. Inoue, and T. Yokoi Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1 J. Clin. Pharmacol. 45 2005 674 682
152. H. Naramoto, T. Uematsu, T. Uchihashi, R. Doto, T. Matsuura, Y. Usui, S. Uematsu, X. Li, M. Takahashi, M. Yamaoka, and K. Furusawa Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines Int. J. Oncol. 30 2007 393 401
153. M.H. Nelson, and C.R. Dolder Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors Ann. Pharmacother. 40 2006 261 269
154. S. Nobili, I. Landini, B. Giglioni, and E. Mini Pharmacological strategies for overcoming multidrug resistance Curr. Drug Targets 7 2006 861 879
155. S. Nobili, I. Landini, T. Mazzei, and E. Mini Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression Med. Res. Rev. 32 2012 1220 1262
156. M.M. O'Brien, N.J. Lacayo, B.L. Lum, S. Kshirsagar, S. Buck, Y. Ravindranath, M. Bernstein, H. Weinstein, M.N. Chang, R.J. Arceci, B.I. Sikic, and G.V. Dahl Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group Pediatr. Blood Cancer 54 2010 694 702
157. T. O'Hare, M.W. Deininger, C.A. Eide, T. Clackson, and B.J. Druker Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia Clin. Cancer Res. 17 2011 212 221
158. T. Oguri, H. Ozasa, T. Uemura, Y. Bessho, M. Miyazaki, K. Maeno, H. Maeda, S. Sato, and R. Ueda MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer Mol. Cancer Ther. 7 2008 1150 1155
159. C. Ozvegy-Laczka, T. Hegedus, G. Varady, O. Ujhelly, J.D. Schuetz, A. Varadi, G. Keri, L. Orfi, K. Nemet, and B. Sarkadi High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter Mol. Pharmacol. 65 2004 1485 1495
160. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris, and H. Varmus EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc. Natl. Acad. Sci. U. S. A. 101 2004 13306 13311
161. H. Parekh, K. Wiesen, and H. Simpkins Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells Biochem. Pharmacol. 53 1997 461 470
162. X.X. Peng, A.K. Tiwari, H.C. Wu, and Z.S. Chen Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myeloid leukemia cells Chin. J. Cancer 31 2012 110 118
163. S.L. Plasschaert, D.M. van der Kolk, E.S. de Bont, W.A. Kamps, K. Morisaki, S.E. Bates, G.L. Scheffer, R.J. Scheper, E. Vellenga, and E.G. de Vries The role of breast cancer resistance protein in acute lymphoblastic leukemia Clin. Cancer Res. 9 2003 5171 5177
164. A. Pozza, J.M. Perez-Victoria, A. Sardo, A. Ahmed-Belkacem, and A. Di Pietro Purification of breast cancer resistance protein ABCG2 and role of arginine-482 Cell. Mol. Life Sci. 63 2006 1912 1922
165. M. Qadir, K.L. O'Loughlin, S.M. Fricke, N.A. Williamson, W.R. Greco, H. Minderman, and M.R. Baer Cyclosporin A is a broad-spectrum multidrug resistance modulator Clin. Cancer Res. 11 2005 2320 2326
166. S.K. Rabindran, D.D. Ross, L.A. Doyle, W. Yang, and L.M. Greenberger Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein Cancer Res. 60 2000 47 50
167. M. Rijavec, M. Silar, N. Triller, I. Kern, U. Cegovnik, M. Kosnik, and P. Korosec Expressions of topoisomerase IIalpha and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients Pathol. Oncol. Res. 17 2011 691 696
168. R.W. Robey, O. Polgar, J. Deeken, K.W. To, and S.E. Bates ABCG2: determining its relevance in clinical drug resistance Cancer Metastasis Rev. 26 2007 39 57
169. E. Rocchi, A. Khodjakov, E.L. Volk, C.H. Yang, T. Litman, S.E. Bates, and E. Schneider The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane Biochem. Biophys. Res. Commun. 271 2000 42 46
170. S.J. Rodig, and G.I. Shapiro Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases Curr. Opin. Investig. Drugs 11 2010 1477 1490
171. D. Rudin, L. Li, N. Niu, K.R. Kalari, J.A. Gilbert, M.M. Ames, and L. Wang Gemcitabine cytotoxicity: interaction of efflux and deamination J. Drug Metab. Toxicol. 2 2011 1 10
172. B. Sarkadi, L. Homolya, G. Szakacs, and A. Varadi Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system Physiol. Rev. 86 2006 1179 1236
173. A. Sauerbrey, W. Sell, D. Steinbach, A. Voigt, and F. Zintl Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia Br. J. Haematol. 118 2002 147 150
174. Z.E. Sauna, M.M. Smith, M. Muller, K.M. Kerr, and S.V. Ambudkar The mechanism of action of multidrug-resistance-linked P-glycoprotein J. Bioenerg. Biomembr. 33 2001 481 491
175. A.H. Schinkel, and J.W. Jonker Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview Adv. Drug Deliv. Rev. 55 2003 3 29
176. A.H. Schinkel, U. Mayer, E. Wagenaar, C.A. Mol, L. van Deemter, J.J. Smit, M.A. van der Valk, A.C. Voordouw, H. Spits, O. van Tellingen, J.M. Zijlmans, W.E. Fibbe, and P. Borst Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins Proc. Natl. Acad. Sci. U. S. A. 94 1997 4028 4033
177. T. Schondorf, C.M. Kurbacher, U.J. Gohring, C. Benz, M. Becker, J. Sartorius, H. Kolhagen, P. Mallman, and R. Neumann Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines Anticancer Res. 22 2002 2199 2203
178. T. Schondorf, A. Scharl, C.M. Kurbacher, O. Bien, M. Becker, R. Neumann, H. Kolhagen, J. Rustemeyer, P. Mallmann, and U.J. Gohring Amplification of the mdr1-gene is uncommon in recurrent ovarian carcinomas Cancer Lett. 146 1999 195 199
179. R. Sen, K. Natarajan, J. Bhullar, S. Shukla, H.B. Fang, L. Cai, Z.S. Chen, S.V. Ambudkar, and M.R. Baer The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2 Mol. Cancer Ther. 11 2012 2033 2044
180. T.N. Shankar, N.V. Shantha, H.P. Ramesh, I.A. Murthy, and V.S. Murthy Toxicity studies on turmeric (Curcuma longa): acute toxicity studies in rats, guinea pigs & monkeys Indian J. Exp. Biol. 18 1980 73 75
181. T. Shen, Y.H. Kuang, C.R. Ashby, Y. Lei, A. Chen, Y. Zhou, X. Chen, A.K. Tiwari, E. Hopper-Borge, J. Ouyang, and Z.S. Chen Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10) PLoS ONE 4 2009 e7520
182. Z. Shi, S. Jain, I.W. Kim, X.X. Peng, I. Abraham, D.T. Youssef, L.W. Fu, K. El Sayed, S.V. Ambudkar, and Z.S. Chen Sipholenol A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells Cancer Sci. 98 2007 1373 1380
183. Z. Shi, Y.J. Liang, Z.S. Chen, X.H. Wang, Y. Ding, L.M. Chen, and L.W. Fu Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein Oncol. Rep. 17 2007 969 976
184. Z. Shi, X.X. Peng, I.W. Kim, S. Shukla, Q.S. Si, R.W. Robey, S.E. Bates, T. Shen, C.R. Ashby Jr., L.W. Fu, S.V. Ambudkar, and Z.S. Chen Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance Cancer Res. 67 2007 11012 11020
185. Z. Shi, A.K. Tiwari, S. Shukla, R.W. Robey, S. Singh, I.W. Kim, S.E. Bates, X. Peng, I. Abraham, S.V. Ambudkar, T.T. Talele, L.W. Fu, and Z.S. Chen Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance Cancer Res. 71 2011 3029 3041
186. S. Shukla, R.W. Robey, S.E. Bates, and S.V. Ambudkar Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2 Drug Metab. Dispos. 37 2009 359 365
187. S. Shukla, C.P. Wu, and S.V. Ambudkar Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges Expert Opin. Drug Metab. Toxicol. 4 2008 205 223
188. B.I. Sikic, G.A. Fisher, B.L. Lum, J. Halsey, L. Beketic-Oreskovic, and G. Chen Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein Cancer Chemother. Pharmacol. 40 Suppl. 1997 S13 S19
189. T.M. Sissung, K. Mross, S.M. Steinberg, D. Behringer, W.D. Figg, A. Sparreboom, and S. Mielke Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia Eur. J. Cancer 42 2006 2893 2896
190. J.B. Smaill, G.W. Rewcastle, J.A. Loo, K.D. Greis, O.H. Chan, E.L. Reyner, E. Lipka, H.D. Showalter, P.W. Vincent, W.L. Elliott, and W.A. Denny Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3, 2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions J. Med. Chem. 43 2000 1380 1397
191. C.D. Smith, J.T. Zilfou, K. Stratmann, G.M. Patterson, and R.E. Moore Welwitindolinone analogues that reverse P-glycoprotein-mediated multiple drug resistance Mol. Pharmacol. 47 1995 241 247
192. K. Sodani, A. Patel, N. Anreddy, S. Singh, D.H. Yang, R.J. Kathawala, P. Kumar, T.T. Talele, and Z.S. Chen Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo Biochem. Pharmacol. 89 2014 52 61
193. K. Sodani, A. Patel, R.J. Kathawala, and Z.S. Chen Multidrug resistance associated proteins in multidrug resistance Chin. J. Cancer 31 2012 58 72
194. P. Sonneveld, M. Schoester, and K. de Leeuw Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells J. Clin. Oncol. 12 1994 1584 1591
195. R. Sordella, D.W. Bell, D.A. Haber, and J. Settleman Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 305 2004 1163 1167
196. A. Sparreboom, J. van Asperen, U. Mayer, A.H. Schinkel, J.W. Smit, D.K. Meijer, P. Borst, W.J. Nooijen, J.H. Beijnen, and O. van Tellingen Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine Proc. Natl. Acad. Sci. U. S. A. 94 1997 2031 2035
197. M. Spitaler, I. Utz, W. Hilbe, J. Hofmann, and H.H. Grunicke PKC-independent modulation of multidrug resistance in cells with mutant (V185) but not wild-type (G185) P-glycoprotein by bryostatin 1 Biochem. Pharmacol. 56 1998 861 869
198. F. Stegmeier, M. Warmuth, W.R. Sellers, and M. Dorsch Targeted cancer therapies in the twenty-first century: lessons from imatinib Clin. Pharmacol. Ther. 87 2010 543 552
199. T. Sumizawa, Z.S. Chen, Y. Chuman, K. Seto, T. Furukawa, M. Haraguchi, A. Tani, N. Shudo, and S.I. Akiyama Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P Mol. Pharmacol. 51 1997 399 405
200. Y.L. Sun, J.J. Chen, P. Kumar, K. Chen, K. Sodani, A. Patel, Y.L. Chen, S.D. Chen, W.Q. Jiang, and Z.S. Chen Reversal of MRP7 (ABCC10)-mediated multidrug resistance by Tariquidar PLOS ONE 8 2013 e55576
201. Y.L. Sun, R.J. Kathawala, S. Singh, K. Zheng, T.T. Talele, W.Q. Jiang, and Z.S. Chen Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance Anticancer Drugs 23 2012 865 873
202. Y.L. Sun, P. Kumar, K. Sodani, A. Patel, Y. Pan, M.R. Baer, Z.S. Chen, and W.Q. Jiang Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells Oncol. Rep. 31 2014 1605 1612
203. A. Suvannasankha, H. Minderman, K.L. O'Loughlin, T. Nakanishi, W.R. Greco, D.D. Ross, and M.R. Baer Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function Leukemia 18 2004 1252 1257
204. G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nat. Rev. Drug Discov. 5 2006 219 234
205. Y. Tabe, M. Konopleva, R. Contractor, M. Munsell, W.D. Schober, L. Jin, Y. Tsutsumi-Ishii, I. Nagaoka, J. Igari, and M. Andreeff Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells Blood 107 2006 1546 1554
206. S. Takayanagi, T. Kataoka, O. Ohara, M. Oishi, M.T. Kuo, and T. Ishikawa Human ATP-binding cassette transporter ABCC10: expression profile and p53-dependent upregulation J. Exp. Ther. Oncol. 4 2004 239 246
207. B. Tan, D. Piwnica-Worms, and L. Ratner Multidrug resistance transporters and modulation Curr. Opin. Oncol. 12 2000 450 458
208. S.C. Tang, J.S. Lagas, N.A. Lankheet, B. Poller, M.J. Hillebrand, H. Rosing, J.H. Beijnen, and A.H. Schinkel Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration Int. J. Cancer 130 2012 223 233
209. H. Thomas, and H.M. Coley Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein Cancer Control 10 2003 159 165
210. S.M. Thomas, and J.R. Grandis Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation Cancer Treat. Rev. 30 2004 255 268
211. A.K. Tiwari, K. Sodani, C.L. Dai, A.H. Abuznait, S. Singh, Z.J. Xiao, A. Patel, T.T. Talele, L. Fu, A. Kaddoumi, J.M. Gallo, and Z.S. Chen Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models Cancer Lett. 328 2013 307 317
212. A.K. Tiwari, K. Sodani, C.L. Dai, C.R. Ashby Jr., and Z.S. Chen Revisiting the ABCs of multidrug resistance in cancer chemotherapy Curr. Pharm. Biotechnol. 12 2011 570 594
213. A.K. Tiwari, K. Sodani, S.R. Wang, Y.H. Kuang, C.R. Ashby Jr., X. Chen, and Z.S. Chen Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters Biochem. Pharmacol. 78 2009 153 161
214. T. Tsuruo, H. Hamada, S. Sato, and Y. Heike Inhibition of multidrug-resistant human tumor growth in athymic mice by anti-P-glycoprotein monoclonal antibodies Jpn. J. Cancer Res. 80 1989 627 631
215. K. Ueda, M.M. Cornwell, M.M. Gottesman, I. Pastan, I.B. Roninson, V. Ling, and J.R. Riordan The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein Biochem. Biophys. Res. Commun. 141 1986 956 962
216. M.M. van den Heuvel-Eibrink, E.A. Wiemer, A. Prins, J.P. Meijerink, P.J. Vossebeld, B. van der Holt, R. Pieters, and P. Sonneveld Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML) Leukemia 16 2002 833 839
217. A. van Loevezijn, J.D. Allen, A.H. Schinkel, and G.J. Koomen Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines Bioorg. Med. Chem. Lett. 11 2001 29 32
218. Y. Vardi, L. Klein, S. Nassar, E. Sprecher, and I. Gruenwald Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men Urology 59 2002 747 752
219. S.G. Vispute, J.J. Chen, Y.L. Sun, K. Sodani, S. Singh, Y. Pan, T. Talele, C.R. Ashby Jr., and Z.S. Chen Vemurafenib (PLX4032, Zelboraf®), a BRAF inhibitor, modulates ABCB1-, ABCG2-, and ABCC10-mediated multidrug resistance J. Cancer Res. Updates 2 2013 306 317
220. J.E. Walker, M. Saraste, M.J. Runswick, and N.J. Gay Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold EMBO J. 1 1982 945 951
221. T. Walle, U.K. Walle, G.N. Kumar, and K.N. Bhalla Taxol metabolism and disposition in cancer patients Drug Metab. Dispos. 23 1995 506 512
222. D.S. Wang, A. Patel, S. Shukla, Y.K. Zhang, Y.J. Wang, R.J. Kathawala, R.W. Robey, L. Zhang, D.H. Yang, T.T. Talele, S.E. Bates, S.V. Ambudkar, R.H. Xu, and Z.S. Chen Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2 Oncotarget 5 2014 4529 4542
223. D.S. Wang, A. Patel, H.M. Sim, Y.K. Zhang, Y.J. Wang, R.J. Kathawala, H. Zhang, T.T. Talele, S.V. Ambudkar, R.H. Xu, and Z.S. Chen ARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2 J. Cell. Biochem. 115 2014 1381 1391
224. P. Wang, Z. Zhang, K. Gao, Y. Deng, J. Zhao, B. Liu, and X. Li Expression and clinical significance of ABCC10 in the patients with non-small cell lung cancer Zhongguo fei ai za zhi Chin. J. Lung Cancer 12 2009 875 878
225. Y.J. Wang, R.J. Kathawala, Y.K. Zhang, A. Patel, P. Kumar, S. Shukla, K.L. Fung, S.V. Ambudkar, T.T. Talele, and Z.S. Chen Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1 Biochem. Pharmacol. 90 2014 367 378
226. Y.J. Wang, Y.K. Zhang, R.J. Kathawala, and Z.S. Chen Repositioning of tyrosine kinase inhibitors as antagonists of ATP-binding cassette transporters in anticancer drug resistance Cancers (Basel) 6 2014 1925 1952
227. S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, H. Rong, C. Chen, X. Zhang, P. Vincent, M. McHugh, Y. Cao, J. Shujath, S. Gawlak, D. Eveleigh, B. Rowley, L. Liu, L. Adnane, M. Lynch, D. Auclair, I. Taylor, R. Gedrich, A. Voznesensky, B. Riedl, L.E. Post, G. Bollag, and P.A. Trail BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res. 64 2004 7099 7109
228. E.R. Wood, A.T. Truesdale, O.B. McDonald, D. Yuan, A. Hassell, S.H. Dickerson, B. Ellis, C. Pennisi, E. Horne, K. Lackey, K.J. Alligood, D.W. Rusnak, T.M. Gilmer, and L. Shewchuk A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res. 64 2004 6652 6659
229. C.P. Wu, C.H. Hsieh, and Y.S. Wu The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy Mol. Pharm. 8 2011 1996 2011
230. X. Xu, C. Leo, Y. Jang, E. Chan, D. Padilla, B.C. Huang, T. Lin, T. Gururaja, Y. Hitoshi, J.B. Lorens, D.C. Anderson, B. Sikic, Y. Luo, D.G. Payan, and G.P. Nolan Dominant effector genetics in mammalian cells Nat. Genet. 27 2001 23 29
231. A.M. Yahanda, K.M. Alder, G.A. Fisher, N.A. Brophy, J. Halsey, R.I. Hardy, M.P. Gosland, B.L. Lum, and B.I. Sikic Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance J. Clin. Oncol. 10 1992 1624 1634
232. D. Yang, R.J. Kathawala, E.E. Chufan, A. Patel, S.V. Ambudkar, Z.S. Chen, and X. Chen Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP) Future Oncol. 10 2014 1827 1841
233. M. Zewail-Foote, and L.H. Hurley Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove J. Med. Chem. 42 1999 2493 2497
234. H. Zhang, R.J. Kathawala, Y.J. Wang, Y.K. Zhang, A. Patel, S. Shukla, R.W. Robey, T.T. Talele, C.R. Ashby Jr., S.V. Ambudkar, S.E. Bates, L.W. Fu, and Z.S. Chen Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance Int. J. Biochem. Cell Biol. 51 2014 111 119
235. H. Zhang, A. Patel, S.L. Ma, X.J. Li, Y.K. Zhang, P.Q. Yang, R.J. Kathawala, Y.J. Wang, N. Anreddy, L.W. Fu, and Z.S. Chen In vitro, in vivo and ex-vivo characterization of ibrutinib: a potent inhibitor of MRP1 efflux function Br. J. Pharmacol. 171 2014 5845 5857
236. H. Zhang, Y.J. Wang, Y.K. Zhang, D.S. Wang, R.J. Kathawala, A. Patel, T.T. Talele, Z.S. Chen, and L.W. Fu AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance Cancer Lett. 350 2014 61 68
237. H. Zhang, Y.K. Zhang, Y.J. Wang, R.J. Kathawala, A. Patel, H. Zhu, K. Sodani, T.T. Talele, S.V. Ambudkar, Z.S. Chen, and L.W. Fu WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells Cancer Sci. 105 2014 1071 1078
238. L.S. Zheng, F. Wang, Y.H. Li, X. Zhang, L.M. Chen, Y.J. Liang, C.L. Dai, Y.Y. Yan, L.Y. Tao, Y.J. Mi, A.K. Yang, K.K. To, and L.W. Fu Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function PLoS ONE 4 2009 e5172
239. W.J. Zhou, X. Zhang, C. Cheng, F. Wang, X.K. Wang, Y.J. Liang, K.K. To, W. Zhou, H.B. Huang, and L.W. Fu Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein Br. J. Pharmacol. 166 2012 1669 1683